Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button

Articles

Page Path
HOME > Intest Res > Volume 15(3); 2017 > Article
Original Article Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
Young Sun Kim1, Sung-Ae Jung2, Kang-Moon Lee3, Soo Jung Park4, Tae Oh Kim5, Chang Hwan Choi6, Hyun Gun Kim7, Won Moon8, Chang Mo Moon2, Hye Kyoung Song2, Soo-Young Na9, Suk-Kyun Yang10, Korean Association for the Study of Intestinal Diseases (KASID)
Intestinal Research 2017;15(3):338-344.
DOI: https://doi.org/10.5217/ir.2017.15.3.338
Published online: June 12, 2017

1Department of Internal Medicine, Seoul National University Healthcare System Gangnam Center, Seoul, Korea.

2Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.

3Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.

4Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

5Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

6Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

7Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

8Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

9Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.

10Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.

Correspondence to Sung-Ae Jung, Department of Internal Medicine, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheongu, Seoul 07985, Korea. Tel: +82-2-2650-5053, Fax: +82-2-2655-2076, jassa@ewha.ac.kr
• Received: April 11, 2016   • Revised: August 7, 2016   • Accepted: August 8, 2016

© Copyright 2017. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 7,215 Views
  • 94 Download
  • 32 Web of Science
  • 32 Crossref
  • 34 Scopus
Full Article

Download PDF Download PDF

  • Background/Aims
    Inflammatory bowel disease (IBD) is a chronic disabling gastrointestinal disorder that diminishes the quality of life of the affected individuals. Limited data are available regarding the impact of IBD on the daily life of Koreans.
  • Methods
    Self-administered, computer-aided, internet-based questionnaires were distributed to members of a Korean patient organization for IBD from March to April 2013, by the Korean Association for the Study of Intestinal Diseases.
  • Results
    A total of 599 patients with IBD (387 with Crohn's disease [CD] and 212 with ulcerative colitis [UC]) were enrolled. The majority of patients (81%) expressed feelings of fatigue, weakness, and being worn out in their daily lives during times of flare; this percentage was reduced to 61% during remission. Respondents were absent from work or school for an average period of 18 days because of illness, within the first 6 months; the majority of respondents (64%) felt stressed about their absence. Forty-six percent of the respondents reported having received unfair comments at work, or having suffered discrimination. Forty-seven percent of the respondents felt that IBD had negatively affected their income and earnings. Compared with patients with UC, those with CD reported a more frequent negative impact of IBD on work, or more economic burden. More than half of the respondents (61%) reported that IBD had prevented them from making or keeping friends.
  • Conclusions
    IBD significantly impacts daily life, including work, education, and social relationships. Treatment that addresses the full spectrum of life of a patient would be more effective.
  • Keywords: Inflammatory bowel disease; Crohn disease; Colitis, ulcerative; Quality of life; Surveys and questionnaires
Although the incidence rate of IBD in Asian countries is considerably lower than the rate in Western countries, the burden of IBD has been rapidly increasing in Korea.123 However, public awareness about IBD is still low in Korea. Delay in the diagnosis of IBD could delay therapy, which can worsen the outcome.4567
IBD mainly consists of UC and CD. These are chronic disabling gastrointestinal disorders that diminish the quality of life (QOL) of the patient.58910 Patients with IBD more frequently receive disability allowances than those received by age-matched individuals from the general population,5610 which proves the detrimental effects of IBD on healthrelated QOL and productivity.58 A recent large-scale study (comprising 4,670 patients with IBD from 25 countries) conducted by the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) reported the detrimental effects of IBD on intimate relationships, and the unfair comments received by the patients with regard to their work performance. 8
However, limited studies have assessed the impact of IBD on the life of patients in Korea, with the majority of studies having been conducted in Western cohorts.568910 In addition, there is little public knowledge regarding IBD and the chronic suffering of patients in Korea.
To overcome these issues, the Korean Association for the Study of Intestinal Diseases (KASID) has been conducting the “Happy Bowel Campaign” since 2013 to raise public awareness of IBD in general and to provide accurate information regarding the importance of early diagnosis and proper treatment to patients with IBD. In addition, the KASID is a promoter of World IBD Day, held every year on May 19.
This study reports the findings of a KASID-sponsored survey that aimed to investigate the impact of IBD on the daily lives of patients in Korea.
1. Study Population
Patients with UC or CD were enrolled. Self-administered, computer-aided, internet-based questionnaires were distributed to them by the KASID, from March to April 2013. The KASID advertised the study through the Korean IBD patient advocacy and support group newsletter and website, and through online advertisements during the Happy Bowel Campaign. The purpose of the study was explained to patients at the time of enrollment. The survey was anonymous and the data were analyzed without revealing the personal details of the patients. Patients who had no Internet access were excluded, since the survey was only available online. Responding to the survey questions was considered consent to participate.
2. Survey
The survey was designed by KASID members of the International Affairs Committee Secretary of Liaison & Public Relations in cooperation with a communications company “Communication Works.” The survey was based primarily on the IMPACT survey of the EFCCA and on previously published reports8 on the QOL of patients with IBD. The survey consisted of 68 questions divided into 6 categories: (1) demographics, (2) experience with IBD, (3) overall impact on life, (4) overall impact on work, (5) overall economic impact, and (6) impact on relationships (Supplementary Material 1).
Some questions regarding “flare” and “remission” were short-answer questions. Most questions were closed ended, and participants were allowed to select one applicable option. The extent of “flare” and “remission” was open to patient interpretation. The questions concerning the overall impact of IBD were measured using a 5-point Likert scale (strongly agree, 5; agree, 4; neither agree nor disagree, 3; disagree, 2; strongly disagree, 1). In these cases, disagree or strongly disagree represented “no” and the other responses represented “yes.”
3. Statistical Analysis
The collected data were analyzed using SPSS for Windows version 22.0 statistical software (IBM Corp., Armonk, NY, USA). With regard to statistical accuracy, a range of ±2.53% (95% CI limits) was set. Descriptive statistics and multiple linear regression analysis were used to analyze the responses, with subanalyses of patients with CD and UC. Subgroup differences were calculated using the chi-square test.
4. Ethics
The study was approved by the Seoul National University Ethics Committee (number: E-1403-037-563), with the completion and return of the survey implying consent to participate.
1. Demographics
A total of 599 patients with IBD (387 [64.6%] with CD and 212 [35.4%] with UC) completed the survey. Demographic and baseline data for all respondents are shown in Fig. 1. The majority of respondents were male (69.6%) in both the CD and UC subgroups. The majority of participants (59%) reported a period of more than 5 years since the diagnosis of IBD (60% of the patients in the CD subgroup and 57% of the patients in the UC subgroup).
2. Experience with IBD
Most respondents (84%) from the CD and UC groups reported IBD being chronically active, whereas 16% reported being in remission. Sixty-five percent of the patients had been admitted to a hospital for IBD within the 5 years preceding the study; however, the proportion of patients with CD was significantly higher than the proportion of patients with UC (76%, P <0.001), with regard to the hospitalization. Thirty-eight percent of the patients received emergency care before being diagnosed with IBD. Eighteen percent of the respondents had experienced a surgical procedure because of IBD. More patients with CD than with UC reported this experience (P <0.001) (Table 1).
Forty-one percent of the respondents reported visiting a hospital 6 months after they noticed the first symptoms related to IBD. The time before the first hospital visit was significantly longer in patients with CD (P <0.001). The reasons for delayed hospital visit were lack of knowledge about IBD (75%), mild symptoms (13%), inconvenient hospital access (3%), economic burden (3%), and others (6%). Most respondents (75%) received a final diagnosis within a year after they first noticed the symptoms. The other 25% patients received a final diagnosis after more than a year; in 3% of these, IBD was diagnosed after 5 years from their first symptoms. The time required for final diagnosis was also significantly longer in patients with CD (P <0.001) (Table 1).
About three-quarters of the respondents reported undergoing current treatment by a gastroenterologist (75%), while 13% reported undergoing current treatment by a primary physician. The most commonly taken drug among the respondents was 5-aminosalicylates (69%), followed by immunosuppressive agents (48%), corticosteroids (15%), and biological drugs (11%). More patients with CD than with UC were being treated with biological drugs (15% and 5%, respectively) at the time of conducting the study. Sixty-one percent of the patients had experienced side effects from corticosteroids, and 87% of the patients were concerned about the long-term effects of corticosteroids.
3. Overall Impact of IBD on Life
The majority of patients (81%) expressed feelings of fatigue, weakness, and being worn out in their daily lives during times of flare; this percentage was reduced to 61% during remission. Most patients (68%) felt stressed and were psychologically affected even during remission. Thirty-seven percent of the patients reported that they felt like committing suicide (CD 41% vs. UC 30%, P =0.01). Multiple linear regression analysis revealed that previous emergency care (P =0.021), previous hospitalizations (P =0.036), previous surgeries (P =0.035), experience of abdominal pain (P=0.008), and using biologics (P =0.020) were associated with the feeling of committing suicide. Most patients (74%) were anxious about their future (Table 2). Young age (P =0.047), low income (P =0.026), and experience of abdominal pain (P <0.001) were associated with anxiety about the future, as per multivariable regression analysis.
4. Overall Impact of IBD on Work
More than half (52%) of the respondents reported absence from work or school because of illness within the past 6 months (mean, 18 days). Younger patients and patients with CD had had more sick days; the mean period absence owing to sickness was 10 days for those >40 years of age and 23 days for those <40 years of age (P <0.001), and 20 days versus 14 days for patients with CD and UC, respectively (P <0.001). The absence from work/school owing to IBD caused stress in 64% of the respondents. Compared to patients with UC, those with CD reported a more frequent negative impact of IBD on work (Table 3). The use of biologics (P =0.007) and steroids (P =0.001), previous hospitalization (P =0.043), previous surgeries (P =0.009), and abdominal pain (P =0.001) were associated with the negative impact of IBD on work, as per multiple linear regression analysis.
5. Overall Economic Impact of IBD
Forty-one percent of the respondents reported decreased QOL owing to the economic burden caused by IBD. Twenty-one percent of the respondents had stopped medical treatment because of the economic burden. Those with CD reported an economic burden more often than those with UC (Table 4). Male gender (P =0.001), old age (P =0.011), low income (P =0.008), use of steroids (P =0.039) and biologics (P =0.023), previous hospitalization (P =0.048), and previous surgeries (P =0.002) were associated with high economic burden, as per multivariable regression analysis.
6. Impact of IBD on Relationships
Sixty-one percent of the patients reported that IBD had prevented them from making or keeping friends. Nearly half of the respondents (47%) reported having had to end an intimate relationship owing to IBD. Most of the respondents (70%) reported that the patient association had a beneficial impact on their life (Table 5). Young age (P =0.002), previous surgeries (P =0.003), and previous hospitalization (P =0.038) were associated with the negative impact of IBD on relationships, as per multivariable regression analysis.
IBD is typically diagnosed in childhood or early adulthood, and is a lifelong condition.58910 Although IBD does not reduce life expectancy, it has a substantial impact on health-related QOL.81112 The present study reports the experience of IBD among Korean patients and the impact of IBD on their daily life. Most patients with IBD were tired, weak and worn out in their daily life during a remission as well as during flareups. A large number of patients reported that IBD adversely affected their QOL. This negative impact of IBD was more severe in patients with CD than in those with UC. A previous experience of surgeries, and hospitalization due to IBD were associated with this negative impact. In general, chronic fatigue has been found to be more prevalent in patients with IBD than in healthy subjects,91314 which, in turn, diminishes the health-related QOL in IBD.9 Accordingly, physicians should remember that fatigue is an important symptom of IBD that impacts the health-related QOL of the patients.
In this study, the time from onset of symptoms of IBD to hospital visit was long; over 41% of the patients had been symptomatic for at least 6 months before visiting a clinician. The most common cause of delayed hospital visit was lack of patient's knowledge about the disease. In addition, although most responders reported establishment of a final diagnosis within 12 months after noticing the first symptoms, 25% of the patients waited for more than a year for the final diagnosis. The delay in meeting a specialist and emergency department visit was more striking for patients with CD than for those with UC. Population-based cohort studies reported that one-fifth to one-third of the patients with CD have complications such as stricture, abscess and/or fistula at the time of diagnosis.1516 Functional gastrointestinal disorders such as IBS often mimic early manifestations of IBD, and infectious diseases such as intestinal tuberculosis, which mimic IBD, can hinder accurate assessment of the disease in Korea, thereby delaying hospital visit or referral to IBD specialists.71718 In the IMPACT survey, only 54% of the 4,670 patients received a final diagnosis within 1 year after noticing the first symptoms. About 20% of the patients received a final diagnosis after more than 5 years. The majority of patients (67%) had visited an emergency department at least once before their diagnosis.8 Timely diagnosis and treatment would help reduce the health care burden of hospitals, including prediagnosis hospital visits or admissions.819 Patients with IBD tend to require emergency room or primary clinic care prior to diagnosis; thus, awareness about IBD is necessary among emergency care staff or primary physicians. 8
About 15% of the respondents received corticosteroid therapy, which was a concern for most of them. Corticosteroid use should be consistent with the guidelines, and the advantages and possible detrimental effects should be discussed with patients.8202122
The fluctuations and unpredictable exacerbations of IBD symptoms have a significant psychological impact on the patient's life. Fears related to the long-term effects of treatments, and the progression of the disease can exacerbate anxiety and depression.11232425 In the present study, 37% of the patients reported having felt like committing suicide. Most patients were anxious about their future. The prevalence of anxiety and/or depression in patients with IBD has been reported to be 35% during remission;24 the prevalence of anxiety and depression during relapse has been reported to be 80% and 60%, respectively.25 In a recent study, Korean patients with IBD showed higher levels of depression and impaired health-related QOL than those shown by healthy controls.26 The negative perceptions of IBD among patients and the depressive mood can increase treatment nonadherence, leading to a poorer outcome.19 Integrating psychological interventions with conventional medical treatment seems prudent.11
IBD had a considerable impact on work and economic burden in the present study. Many patients, especially young respondents and those with CD, had missed school or work in the 6 months prior to the study, consistent with other reports,827 which, for many patients, is a source of stress and can be the basis for hurtful comments or employment problems. Accordingly, medical discussions should consider work and economic burden as important facets of treatment among Korean patients with IBD.
With regard to building human relationships, IBD can lead to decreased physical intimacy and social activity.2829 Being able to talk about IBD-related problems in a supportive group setting was helpful for many respondents, as was the awareness created by health care professionals regarding the influence of IBD on these aspects of life.
This study had several limitations. Firstly, the survey was a self-completed instrument and was only available online, so individuals without Internet access could not participate. Thus, the results cannot be generalized to the entire population. Secondly, the survey questionnaire was not validated. Finally, self-assessment introduces the possibility of recall bias concerning aspects such as medication use and emergency care. Some patients might have overestimated the negative impact of IBD on their lives.
Despite the limitations, our study is meaningful because it is the first large-scale study to investigate the effects on IBD on the daily life of Korean patients. The results would be valuable in devising strategies of care, and campaigns to increase the awareness of IBD in Korea.
In conclusion, IBD considerably affects the daily life of the patients, including their work, school, and social relationships. Treatment that addresses that full spectrum of a patient's life would be more effective.

Financial support: None.

Conflict of interest: None.

A Survey of Patients with Inflammatory Bowel Disease (IBD)
ir-15-338-s001.pdf
  • 1. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542–549.PMID: 17941073.ArticlePubMed
  • 2. Lee JW, Im JP, Cheon JH, Kim YS, Kim JS, Han DS. Inflammatory bowel disease cohort studies in Korea: present and future. Intest Res 2015;13:213–218.PMID: 26130995.ArticlePubMedPMC
  • 3. Choi JH, Kim ES, Cho KB, et al. Old age at diagnosis is associated with favorable outcomes in Korean patients with inflammatory bowel disease. Intest Res 2015;13:60–67.PMID: 25691844.ArticlePubMedPMC
  • 4. Sewell JL, Velayos FS. Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis 2013;19:627–643.PMID: 22623078.ArticlePubMedPMC
  • 5. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241–247.PMID: 21646246.ArticlePubMed
  • 6. Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol 2012;107:1770–1776.PMID: 23211844.ArticlePubMedPDF
  • 7. Hu PJ. Inflammatory bowel disease in Asia: the challenges and opportunities. Intest Res 2015;13:188–190.PMID: 26130991.ArticlePubMedPMC
  • 8. Lönnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L. IBD and health-related quality of life: discovering the true impact. J Crohns Colitis 2014;8:1281–1286.PMID: 24662394.ArticlePubMedPDF
  • 9. Romberg-Camps MJ, Bol Y, Dagnelie PC, et al. Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort. Inflamm Bowel Dis 2010;16:2137–2147.PMID: 20848468.ArticlePubMed
  • 10. Haapamäki J, Roine RP, Sintonen H, Turunen U, Färkkilä MA, Arkkila PE. Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. Qual Life Res 2010;19:919–928.PMID: 20361263.ArticlePubMed
  • 11. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P. Psychological issues in inflammatory bowel disease: an overview. Gastroenterol Res Pract 2012;2012:106502PMID: 22778720.ArticlePubMedPMCPDF
  • 12. Hall NJ, Rubin GP, Dougall A, Hungin AP, Neely J. The fight for ‘health-related normality’: a qualitative study of the experiences of individuals living with established inflammatory bowel disease (IBD). J Health Psychol 2005;10:443–455.PMID: 15857873.ArticlePubMed
  • 13. Jelsness-Jørgensen LP, Bernklev T, Henriksen M, Torp R, Moum BA. Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:106–114.PMID: 21083587.ArticlePubMed
  • 14. Yoo S, Jung YS, Park JH, et al. Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease. Gut Liver 2014;8:148–153.PMID: 24672655.ArticlePubMed
  • 15. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010;139:1147–1155.PMID: 20637205.ArticlePubMedPMC
  • 16. Kim YS. What is the important issue to prevent the postoperative Crohn's disease? Intest Res 2014;12:85–86.PMID: 25349572.ArticlePubMedPMC
  • 17. Danese S, Fiorino G, Mary JY, et al. Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. J Crohns Colitis 2015;9:601–606.PMID: 25908718.ArticlePubMedPDF
  • 18. Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver 2010;4:1–14.PMID: 20479907.ArticlePubMedPMC
  • 19. Devlen J, Beusterien K, Yen L, Ahmed A, Cheifetz AS, Moss AC. The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis 2014;20:545–552.PMID: 24407484.ArticlePubMedPMC
  • 20. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010;4:28–62.PMID: 21122489.ArticlePubMedPDF
  • 21. Ye BD, Yang SK, Shin SJ, et al. Guidelines for the management of Crohn's disease. Intest Res 2012;10:26–66.Article
  • 22. Choi CH, Kim YH, Kim YS, et al. Guidelines for the management of ulcerative colitis. Intest Res 2012;10:1–25.Article
  • 23. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol 2008;103:1989–1997.PMID: 18796096.ArticlePubMed
  • 24. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004;66:79–84.PMID: 14747641.ArticlePubMed
  • 25. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997;32:1013–1021.PMID: 9361174.ArticlePubMed
  • 26. Kim ES, Cho KB, Park KS, et al. Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders. J Clin Gastroenterol 2013;47:e38–e44.PMID: 23090047.ArticlePubMed
  • 27. Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006;12:402–412.PMID: 16670530.ArticlePubMed
  • 28. Daniel JM. Young adults' perceptions of living with chronic inflammatory bowel disease. Gastroenterol Nurs 2002;25:83–94.PMID: 12055376.ArticlePubMed
  • 29. Kemp K, Griffiths J, Lovell K. Understanding the health and social care needs of people living with IBD: a meta-synthesis of the evidence. World J Gastroenterol 2012;18:6240–6249.PMID: 23180944.ArticlePubMedPMC
Fig. 1

Baseline characteristics of patients with IBD. aP <0.05, compared with patients with UC.

ir-15-338-g001.jpg
Table 1

Experience with IBD

ir-15-338-i001.jpg
CD (n=387) UC (n=212) P-value
Current status of IBD
 Chronically active condition 325 (84) 178 (84) 1.000
 In remission 62 (16) 34 (16) 1.000
Hospitalization in the past 5 yr 294 (76) 98 (46) <0.001
Emergency care before diagnosis of IBD 186 (48) 40 (19) <0.001
Previous surgeries owing to IBD 190 (49) 13 (6) <0.001
Time to hospital visit since noticing first symptoms (mo)
 <6 208 (54) 145 (68) <0.001
 ≥6 179 (46) 67 (32) <0.001
Time required to receive the final diagnosis since noticing the first symptoms (mo)
 <6 199 (51) 144 (68) <0.001
 6–12 77 (20) 29 (14) 0.058
 >12 112 (29) 38 (18) 0.003

Values are presented as number (%).

Table 2

Overall Impact of IBD on Daily Life

ir-15-338-i002.jpg
CD (n=387) UC (n=212) P-value
Felt tired, weak, and worn out in daily life during flare-ups 311 (80) 174 (81) 0.664
Felt tired, weak, and worn out in daily life during remission 238 (61) 127 (60) 0.727
Felt stressed and psychologically affected during remission 270 (69) 137 (64) 0.201
Having felt like committing suicide 158 (41) 64 (30) 0.010
Having felt anxiety about the future 302 (78) 141 (67) 0.003

Values are presented as number (%).

Table 3

Overall Impact of IBD on Work

ir-15-338-i003.jpg
CD (n=387) UC (n=212) P-value
Cancelled or rescheduled an appointment 238 (62) 121 (57) 0.297
Left office or school early 220 (57) 80 (38) <0.001
Absence from work or school 228 (59) 83 (39) <0.001
Felt stress about taking time off work or school 271 (70) 112 (53) <0.001
Received unfair comments at work or school 155 (40) 52 (25) <0.001
Suffered discrimination or were ostracized 52 (14) 14 (7) 0.010
Decline in income or academic ability 200 (52) 80 (38) 0.010
Unable to perform to their full potential 252 (66) 119 (56) 0.035

Values are presented as number (%).

Table 4

Overall Economic Impact of IBD

ir-15-338-i004.jpg
CD (n=387) UC (n=212) P-value
Stopped medical treatment owing to economic burden 96 (25) 30 (14) 0.002
IBD had negatively affected the income 201 (52) 180 (38) <0.001
Sorry for the family bearing treatment cost 244 (63) 79 (37) <0.001
Decreased quality of life owing to the economic burden 170 (44) 77 (36) 0.082

Values are presented as number (%).

Table 5

Impact of IBD on Relationships

ir-15-338-i005.jpg
CD (n=387) UC (n=212) P-value
Prevented from making or keeping friends 237 (62) 126 (59) 0.663
Had to end an intimate relationship end owing to IBD 182 (47) 100 (47) 1.000
Felt stressed about keeping intimate family relationships 155 (40) 85 (40) 1.000
Meeting others with IBD made them more optimistic 120 (31) 67 (32) 0.927
Patient association had a beneficial impact on their life 258 (67) 161 (76) 0.020

Values are presented as number (%).

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017
      Chung Sang Tse, Chien-Hsiang Weng, Michelle Kwon, Courtney Benjamin Wolk, Lily A Brown, Kanika Malani, Samir A Shah, Sean D Fine
      Inflammatory Bowel Diseases.2024; 30(1): 150.     CrossRef
    • Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
      Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
      The Korean Journal of Internal Medicine.2024; 39(1): 68.     CrossRef
    • Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
      Chong Kim, Fiona L. Brown, Caroline Burk, Milena Anatchkova, Nashmel Sargalo, Ankita Kaushik
      Quality of Life Research.2024; 33(5): 1373.     CrossRef
    • Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis
      Ji Yeon Noh, Naser Farhataziz, Michael T. Kinter, Xin Yan, Yuxiang Sun
      Metabolites.2024; 14(4): 194.     CrossRef
    • Patient Advisory Groups in Inflammatory Bowel Disease: A Collaborative Relationship Between Patients and Researchers
      Linda Yoo, Mara Shapiro, Ihsan Kahveci, Isabela Hernandez, Rachael Whittemore, Tanvi Kale, Samantha Winders, Kendra Kamp
      Crohn's & Colitis 360.2024;[Epub]     CrossRef
    • A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease
      Heidi Glynn, Simon R. Knowles
      Clinical Nursing Research.2023; 32(1): 159.     CrossRef
    • Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases
      Johanna Holman, Molly Hurd, Peter L. Moses, Gary M. Mawe, Tao Zhang, Suzanne L. Ishaq, Yanyan Li
      The Journal of Nutritional Biochemistry.2023; 113: 109238.     CrossRef
    • Medical consultation in ulcerative colitis: Key elements for improvement
      Yago González-Lama, Elena Ricart, Ana Cábez, Pilar Fortes, Susana Gómez, Francesc Casellas
      World Journal of Gastroenterology.2023; 29(6): 917.     CrossRef
    • The relationship of major depressive disorder with Crohn's disease activity
      Carolina Bortolozzo Graciolli Facanali, Carlos Walter Sobrado Junior, Renério Fraguas Junior, Marcio Roberto Facanali Junior, Lucas Rodrigues Boarini, Lucas Faraco Sobrado, Ivan Cecconello
      Clinics.2023; 78: 100188.     CrossRef
    • Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
      Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
      Yonsei Medical Journal.2023; 64(9): 541.     CrossRef
    • The impact of gastrointestinal conditions on psychosocial factors associated with the biopsychosocial model of health: A scoping review
      Elizabeth Dent, Nicola Davinson, Stephanie Wilkie
      Applied Psychology: Health and Well-Being.2022; 14(2): 626.     CrossRef
    • Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway
      Yao Li, Xu Yang, Jia-ni Yuan, Rui Lin, Yun-yuan Tian, Yu-xin Li, Yan Zhang, Xu-fang Wang, Yan-hua Xie, Si-wang Wang, Xiao-hui Zheng
      Frontiers in Pharmacology.2022;[Epub]     CrossRef
    • The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care
      Nosheen Umar, Dominic King, Joht Singh Chandan, Neeraj Bhala, Krish Nirantharakumar, Nicola Adderley, Dawit T. Zemedikun, Phil Harvey, Nigel Trudgill
      Alimentary Pharmacology & Therapeutics.2022; 56(5): 814.     CrossRef
    • Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis
      Qin Xiong, Fuyou Tang, Yilin Li, Fengjiao Xie, Lei Yuan, Chengjiao Yao, Ruike Wu, Juan Wang, Qiuxiang Wang, Peimin Feng
      Journal of Psychosomatic Research.2022; 160: 110983.     CrossRef
    • Modelling symptoms to suicide risk in individuals with inflammatory bowel disease
      Valentina Mihajlovic, Dean A Tripp, Jill A Jacobson
      Journal of Health Psychology.2021; 26(12): 2143.     CrossRef
    • Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood
      Wei-Sheng Chung, Sunny Chung, Chung-Y Hsu, Cheng-Li Lin
      Frontiers in Medicine.2021;[Epub]     CrossRef
    • Gastrointestinal microbiome, what is behind faecal microbiota transplantation?
      P. Thomson, P. Núñez, R. Quera, C. Bay
      New Microbes and New Infections.2021; 42: 100898.     CrossRef
    • Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
      Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
      Gut and Liver.2020; 14(1): 89.     CrossRef
    • Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management
      G. Pellino, D. S. Keller, G. M. Sampietro, V. Annese, M. Carvello, V. Celentano, C. Coco, F. Colombo, N. Cracco, F. Di Candido, M. Franceschi, S. Laureti, G. Mattioli, L. Pio, G. Sciaudone, G. Sica, V. Villanacci, R. Zinicola, S. Leone, S. Danese, A. Spin
      Techniques in Coloproctology.2020; 24(2): 105.     CrossRef
    • Inflammatory bowel disease fatigue: an analysis of definitions, risk factors and impact and their implications for assessment and management
      Doireann Ni Dhalaigh, Anna Marie Greaney, Dawn Farrell
      Gastrointestinal Nursing.2020; 18(5): 42.     CrossRef
    • Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
      Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
      Gut and Liver.2020; 14(4): 459.     CrossRef
    • Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
      Francesc Casellas, Daniel Guinard Vicens, Santiago García-López, Yago González-Lama, Federico Argüelles-Arias, Manuel Barreiro-de Acosta, Laura Marín Sánchez, Juan Manuel Mendive, Roberto Saldaña, Ana Cabez, Susana Gómez, Estíbaliz Loza
      European Journal of Gastroenterology & Hepatology.2020; 32(12): 1514.     CrossRef
    • Preconception Care Program for Women with Inflammatory Bowel Disease Using Intervention Mapping: A Protocol for Program Development
      Young Jin Lee, Yeon Hee Kim, Hae Won Kim
      International Journal of Environmental Research and Public Health.2020; 17(24): 9365.     CrossRef
    • Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease
      Jing Zhou, Lu-Yi Wu, Liu Chen, Ya-Jing Guo, Yi Sun, Tao Li, Ji-Meng Zhao, Chun-Hui Bao, Huan-Gan Wu, Yin Shi
      World Journal of Gastroenterology.2019; 25(17): 2071.     CrossRef
    • EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
      María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
      Therapeutic Advances in Gastroenterology.2019;[Epub]     CrossRef
    • Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy
      Zili Lin, Huiyi Wu, Yiming Fu, Shixue Dai
      Inflammatory Bowel Diseases.2019; 25(12): 1886.     CrossRef
    • Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission
      Dominika Głąbska, Dominika Guzek, Gustaw Lech
      Nutrients.2019; 11(10): 2333.     CrossRef
    • Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease
      Alexander Palant, Wolfgang Himmel
      BMJ Open.2019; 9(1): e022642.     CrossRef
    • Reactive Oxygen Species Deficiency Due to Ncf1-Mutation Leads to Development of Adenocarcinoma and Metabolomic and Lipidomic Remodeling in a New Mouse Model of Dextran Sulfate Sodium-Induced Colitis
      Lina Carvalho, Joana R. M. Gomes, Ludgero C. Tavares, Ana R. Xavier, Karel D. Klika, Rikard Holmdahl, Rui A. Carvalho, M. Margarida Souto-Carneiro
      Frontiers in Immunology.2018;[Epub]     CrossRef
    • Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile
      Antonia Fernández, Daniela Simian, Rodrigo Quera, Lilian Flores, Patricio Ibáñez, Jaime Lubascher, Carolina Figueroa, Udo Kronberg, Gonzalo Pizarro, Daniela Fluxá
      Complementary Therapies in Medicine.2018; 40: 77.     CrossRef
    • IBD2020 global forum: results of an international patient survey on quality of care
      Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
      Intestinal Research.2018; 16(4): 537.     CrossRef
    • Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
      Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
      Gut and Liver.2018; 12(5): 544.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
      Intest Res. 2017;15(3):338-344.   Published online June 12, 2017
      DOI: https://doi.org/10.5217/ir.2017.15.3.338
      Close
    • XML DownloadXML Download
    Figure
    • 0
    Related articles
    Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
    Image
    Fig. 1 Baseline characteristics of patients with IBD. aP <0.05, compared with patients with UC.

    Fig. 1

    Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases

    Experience with IBD

    CD (n=387)UC (n=212)P-value
    Current status of IBD
     Chronically active condition325 (84)178 (84)1.000
     In remission62 (16)34 (16)1.000
    Hospitalization in the past 5 yr294 (76)98 (46)<0.001
    Emergency care before diagnosis of IBD186 (48)40 (19)<0.001
    Previous surgeries owing to IBD190 (49)13 (6)<0.001
    Time to hospital visit since noticing first symptoms (mo)
     <6208 (54)145 (68)<0.001
     ≥6179 (46)67 (32)<0.001
    Time required to receive the final diagnosis since noticing the first symptoms (mo)
     <6199 (51)144 (68)<0.001
     6–1277 (20)29 (14)0.058
     >12112 (29)38 (18)0.003

    Values are presented as number (%).

    Overall Impact of IBD on Daily Life

    CD (n=387)UC (n=212)P-value
    Felt tired, weak, and worn out in daily life during flare-ups311 (80)174 (81)0.664
    Felt tired, weak, and worn out in daily life during remission238 (61)127 (60)0.727
    Felt stressed and psychologically affected during remission270 (69)137 (64)0.201
    Having felt like committing suicide158 (41)64 (30)0.010
    Having felt anxiety about the future302 (78)141 (67)0.003

    Values are presented as number (%).

    Overall Impact of IBD on Work

    CD (n=387)UC (n=212)P-value
    Cancelled or rescheduled an appointment238 (62)121 (57)0.297
    Left office or school early220 (57)80 (38)<0.001
    Absence from work or school228 (59)83 (39)<0.001
    Felt stress about taking time off work or school271 (70)112 (53)<0.001
    Received unfair comments at work or school155 (40)52 (25)<0.001
    Suffered discrimination or were ostracized52 (14)14 (7)0.010
    Decline in income or academic ability200 (52)80 (38)0.010
    Unable to perform to their full potential252 (66)119 (56)0.035

    Values are presented as number (%).

    Overall Economic Impact of IBD

    CD (n=387)UC (n=212)P-value
    Stopped medical treatment owing to economic burden96 (25)30 (14)0.002
    IBD had negatively affected the income201 (52)180 (38)<0.001
    Sorry for the family bearing treatment cost244 (63)79 (37)<0.001
    Decreased quality of life owing to the economic burden170 (44)77 (36)0.082

    Values are presented as number (%).

    Impact of IBD on Relationships

    CD (n=387)UC (n=212)P-value
    Prevented from making or keeping friends237 (62)126 (59)0.663
    Had to end an intimate relationship end owing to IBD182 (47)100 (47)1.000
    Felt stressed about keeping intimate family relationships155 (40)85 (40)1.000
    Meeting others with IBD made them more optimistic120 (31)67 (32)0.927
    Patient association had a beneficial impact on their life258 (67)161 (76)0.020

    Values are presented as number (%).
    Table 1 Experience with IBD

    Values are presented as number (%).

    Table 2 Overall Impact of IBD on Daily Life

    Values are presented as number (%).

    Table 3 Overall Impact of IBD on Work

    Values are presented as number (%).

    Table 4 Overall Economic Impact of IBD

    Values are presented as number (%).

    Table 5 Impact of IBD on Relationships

    Values are presented as number (%).

    Table 1

    Table 2

    Table 3

    Table 4

    Table 5

    Intest Res : Intestinal Research
    © Korean Association for the Study of Intestinal Diseases.
    Close layer
    TOP